相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
Petr Szturz et al.
ORAL ONCOLOGY (2020)
The Role of Cancer Stem Cells in Radiation Resistance
Christoph Reinhold Arnold et al.
FRONTIERS IN ONCOLOGY (2020)
Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review
Viktor Wichmann et al.
ACTA ONCOLOGICA (2020)
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Karol Bukowski et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model
Cheng-Yu Yang et al.
PLOS ONE (2020)
Anti-angiogenesis: Opening a new window for immunotherapy
Feifei Guo et al.
LIFE SCIENCES (2020)
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial
Vijay Patil et al.
Lancet Global Health (2020)
Head and Neck Cancer
Laura Q. M. Chow
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden
D. Hashim et al.
ANNALS OF ONCOLOGY (2019)
Cordycepin, isolated from medicinal fungus Cordyceps sinensis, enhances radiosensitivity of oral cancer associated with modulation of DNA damage repair
Nai-Wen Su et al.
FOOD AND CHEMICAL TOXICOLOGY (2019)
Survival outcomes after treatment of cancer of the oral cavity (1985-2015)
Daniella Karassawa Zanoni et al.
ORAL ONCOLOGY (2019)
HMGA2 Contributes to Distant Metastasis and Poor Prognosis by Promoting Angiogenesis in Oral Squamous Cell Carcinoma
Junki Sakata et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment
Yidi Qu et al.
MOLECULAR CANCER (2019)
Cancer stem cell self-renewal as a therapeutic target in human oral cancer
Jinwei Hu et al.
ONCOGENE (2019)
Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science
Yuening Xiang et al.
CANCER MEDICINE (2019)
Oral Cavity Cancer in the Indian Subcontinent - Challenges and Opportunities
N. Mummudi et al.
CLINICAL ONCOLOGY (2019)
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Shang-Hung Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer
Vijay M. Patil et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Metronomic chemotherapy option for advanced oral cancer
Elizabeth Gourd
LANCET ONCOLOGY (2019)
Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry
Seung-Ki Min et al.
ORAL ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model
Cheng-Yu Yang et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma
Melanie Boxberg et al.
JOURNAL OF IMMUNOLOGY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells
David M. Peereboom et al.
JCI INSIGHT (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The Impact of Metronomic Adjuvant Chemotherapy in Patients with Advanced Oral Cancer
Ming-Yu Hsieh et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway
Jing Yang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
Gianfranco Natale et al.
CANCER LETTERS (2018)
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients
Teresa Di Desidero et al.
INVESTIGATIONAL NEW DRUGS (2018)
Adjuvant radiotherapy after curative surgery for oral cavity squamous cell carcinoma and treatment effect of timing and duration on outcome-A Taiwan Cancer Registry national database analysis
Yung-Jen Cheng et al.
CANCER MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer
Roberto Filippi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Targeting Cancer Stem Cells to Overcome Chemoresistance
Toni Nunes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Current achievements and future perspectives of metronomic chemotherapy
Adriana Romiti et al.
INVESTIGATIONAL NEW DRUGS (2017)
A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
Irina Kareva
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma
Jacek Mackiewicz et al.
MEDICINE (2017)
Metronomic Cordycepin Therapy Prolongs Survival of Oral Cancer-Bearing Mice and Inhibits Epithelial-Mesenchymal Transition
Nai-Wen Su et al.
MOLECULES (2017)
Role of vascular normalization in benefit from metronomic chemotherapy
Fotios Mpekris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors A Randomized Clinical Trial
Raja Pramanik et al.
JAMA ONCOLOGY (2017)
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
M. E. Cazzaniga et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2017)
Human papillomavirus-related oropharyngeal cancer
M. Taberna et al.
ANNALS OF ONCOLOGY (2017)
Metronomic chemotherapy and immunotherapy in cancer treatment
Yu-Li Chen et al.
CANCER LETTERS (2017)
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial
Emilia Montagna et al.
CANCER LETTERS (2017)
Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation
Eirini Biziota et al.
CANCER LETTERS (2017)
The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease
Robert S. Kerbel et al.
CANCER LETTERS (2017)
Metronomic chemotherapy in metastatic colorectal cancer
In Sook Woo et al.
CANCER LETTERS (2017)
Tackling pancreatic cancer with metronomic chemotherapy
Adriana Romiti et al.
CANCER LETTERS (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives
Ioana Lambrescu et al.
CANCER TREATMENT REVIEWS (2017)
Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response
Herman Andres Perroud et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Trends in oral cavity cancer incidence, mortality, survival and treatment in the Netherlands
Boukje A. C. van Dijk et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
Tze-Sian Chan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Implications of cancer stem cells in developing therapeutic resistance in oral cancer
Prajna Paramita Naik et al.
ORAL ONCOLOGY (2016)
Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998-2006
Zachary G. Schwam et al.
ORAL ONCOLOGY (2016)
Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
Andrea Camerini et al.
BMC CANCER (2015)
A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment
Robert S. Kerbel
CANCER JOURNAL (2015)
Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them
Qian Tan et al.
CANCER JOURNAL (2015)
Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
Irina Kareva et al.
CANCER LETTERS (2015)
Oral uracil and tegafur as postoperative adjuvant metronomic chemotherapy in patients with advanced oral squamous cell carcinoma
Jiun-Sheng Lin et al.
JOURNAL OF DENTAL SCIENCES (2015)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck
Vijay Maruti Patil et al.
ORAL ONCOLOGY (2015)
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine
Sebastien Benzekry et al.
SEMINARS IN CANCER BIOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area
Chun-Ta Liao et al.
ORAL ONCOLOGY (2014)
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Xenofon Papanikolaou et al.
HAEMATOLOGICA (2013)
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
Marta Vives et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells
Tarannum Ferdous et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Emma L. Barber et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2013)
Has the time come for metronomics in low-income and middle-income countries?
Nicolas Andre et al.
LANCET ONCOLOGY (2013)
Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
Ilkka Liikanen et al.
MOLECULAR THERAPY (2013)
Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer
Niharika Sinha et al.
ORAL ONCOLOGY (2013)
Expression of Angiopoietin-2 and Vascular Endothelial Growth Factor Receptor-3 Correlates with Lymphangiogenesis and Angiogenesis and Affects Survival of Oral Squamous Cell Carcinoma
Chao Li et al.
PLOS ONE (2013)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
Giacomo Allegrini et al.
ANGIOGENESIS (2012)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
Eva Ellebaek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
Nicolas Penel et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Cancer stem cells: an evolving concept
Long V. Nguyen et al.
NATURE REVIEWS CANCER (2012)
Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer
Tohru Furusaka et al.
ACTA OTO-LARYNGOLOGICA (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Biology of Cox-2: An Application in Cancer Therapeutics
Zakir Khan et al.
CURRENT DRUG TARGETS (2011)
Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma
Olivier Mir et al.
EUROPEAN JOURNAL OF CANCER (2011)
Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC)
Lorraine Walsh et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment
Thais Helena Gasparoto et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity
Laetitia Aymeric et al.
CANCER RESEARCH (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPα during oral cancer suppression
Kuo-Wei Chang et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
Chih-Hung Hsu et al.
JOURNAL OF HEPATOLOGY (2010)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Claire Banissi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Classification of Chemotherapeutic Agents Based on Their Differential In vitro Effects on Dendritic Cells
Hiroaki Tanaka et al.
CANCER RESEARCH (2009)
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Jennifer L. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivo
Yuan-Wu Chen et al.
ORAL ONCOLOGY (2009)
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
G. Allegrini et al.
BRITISH JOURNAL OF CANCER (2008)
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
Yuval Shaked et al.
CANCER CELL (2008)
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis
Mitchell Machtay et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
Chris Folkins et al.
CANCER RESEARCH (2007)
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
Yuval Shaked et al.
SCIENCE (2006)
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
G Bocci et al.
ANNALS OF ONCOLOGY (2005)
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis
Y Shaked et al.
CANCER CELL (2005)
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens
U Emmenegger et al.
CANCER RESEARCH (2004)
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
J Bernier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck
JS Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
JY Wang et al.
ANTI-CANCER DRUGS (2003)
Metronomic scheduling: the future of chemotherapy?
G Gasparini
LANCET ONCOLOGY (2001)
分享论文
